Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rolaids Recall Roils McNeil As Year Of OTC Manufacturing Errors Winds Down

This article was originally published in The Tan Sheet

Executive Summary

McNeil Consumer Healthcare ends 2010 much as it began the year: recalling an OTC product potentially contaminated by a third party – Rolaids Softchews in this case.
Advertisement

Related Content

Chattem To Revive Rolaids Line Bought From J&J
Chattem To Revive Rolaids Line Bought From J&J
McNeil OTC Recalls Slice $900M From J&J's 2010 Sales
Perrigo Banks On Product Launches, OTC Switches For "Significant Growth"
Rolaids Recall Puts Contract Manufacturers In Issa's Crosshairs
J&J Fills Consumer Chief Post, Promotes Likely CEO Candidates
House FDA Investigation Previews Oversight Shift Under GOP
J&J/McNeil Done With Post-Recall Personnel Changes - CEO Weldon
McNeil Expands Tylenol Recall As FDA Criticizes Firm's Response To AERs
McNeil Expands Tylenol Recall As FDA Criticizes Firm's Response To AERs

Topics

Advertisement
UsernamePublicRestriction

Register

PS104740

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel